Praxis Reassesses Vormatrigine Program After Pivotal Epilepsy Study Misses Primary Endpoint

Praxis Precision Medicines Inc. (NASDAQ:PRAX) on Monday reported results from its Phase 2/3 POWER1 study of vormatrigine for focal onset seizures.
The company said the overall outcome fell short of expectations but highlighted encouraging findings from the higher-dose treatment arm.
Higher-Dose Arm Shows Encouraging Signal Despite Trial Outcome
The study in highly refractory patients with focal onset seizures did not meet its primary success measure of change in monthly seizure frequency.
Focal onset seizures (formerly called a partial seizure) begin in a specific, localized area on one side of the brain.
Secondary measure, the 50% response rate, was met, and seizure reduction during the second half of the study on the higher dose (30 mg) was more pronounced.
"While the results for POWER1